Biopharmaceutical company Sigilon Therapeutics reported on Thursday the election of David E. Moller, MD as its chief scientific officer.

Most recently, Dr Moller has served in Eli Lilly as vice president of Business Development - Emerging Technology and Innovation at Eli Lilly as well as vice president of its Endocrine and Cardiovascular Research and Clinical Investigation .

Previously, Dr Moller was employed as vice president, Metabolic Disorders at Merck (MSD), which included oversight of the team responsible for the discovery of sitaglipitin (Januvia), leading the global discovery efforts in diabetes and obesity.

Earlier in his career, Dr Moller was part of the faculty of Harvard Medical School.